We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

51 hedge funds and large institutions have $61.1M invested in Arbutus Biopharma in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

4% more funds holding

Funds holding: 49 → 51 (+2)

16% less call options, than puts

Call options by funds: $470K | Put options by funds: $560K

16% less capital invested

Capital invested by funds: $73.1M → $61.1M (-$12M)

18% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 17

Holders
51
Holders Change
+2
Holders Change %
+4.08%
% of All Funds
1.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
14
Reduced
17
Closed
6
Calls
$470K
Puts
$560K
Net Calls
-$90K
Net Calls Change
-$239K

Top Buyers

1
AC
Armistice Capital
New York
+$1.73M
2
IGIM
I.G. Investment Management
Manitoba, Canada
+$1.06M
3
Deutsche Bank
Deutsche Bank
Germany
+$423K
4
Morgan Stanley
Morgan Stanley
New York
+$251K
5
KPF
K2 Principal Fund
Ontario, Canada
+$143K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$896K
2
Renaissance Technologies
Renaissance Technologies
New York
-$840K
3
DCM
Dialectic Capital Management
Connecticut
-$740K
4
SFM
Sphera Funds Management
Israel
-$654K
5
BG
Bellevue Group
Switzerland
-$516K
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
51
Caxton Corporation
New Jersey
– -$173K -41,903 Closed
AGM
52
Alpine Global Management
New York
– -$43K -10,434 Closed
WIC
53
Woodmont Investment Counsel
Tennessee
– -$3K -800 Closed
PCM
54
Prelude Capital Management
New York
– +$423 +100 New
IA
55
IFP Advisors
Florida
– +$466 +110 New
1 2
3

ABUS Hedge Fund Activity: Q2 2016 in Review

51 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2016, worth a combined $61.1M — down 16% from $73.1M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ABUS positions and 6 closed out — a net gain of 2 holders — while 14 added to existing stakes and 17 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.73M. The largest seller was Millennium Management, cutting an estimated $896K.

  • 51 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2016, up from 49 in Q1 2016.
  • Funds reported $61.1M of Arbutus Biopharma stock for Q2 2016, down 16% quarter-over-quarter.
  • 8 funds opened new Arbutus Biopharma positions in Q2 2016 and 6 closed out, a net change of +2 holders.
  • The largest Arbutus Biopharma buyer in Q2 2016 was Armistice Capital, an estimated $1.73M added.
  • The largest Arbutus Biopharma seller in Q2 2016 was Millennium Management, an estimated $896K sold.

Based on aggregated 13F filings for Q2 2016.